Revive
Therapeutics Announces
Successful
Research Results for
Psilocybin to Treat Traumatic Brain Injury and
Filing
of International
Patent Application
TORONTO,
March
19, 2021 --
InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or
the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company
focused on the research and development of therapeutics for medical
needs and rare disorders, is pleased to
announce
positive
results
of a pre-clinical study evaluating the
efficacy of psilocybin in the treatment of mild traumatic brain
injury ("TBI")
in a
rodent model of TBI.
The study
was conducteding
at the
National Health Research Institutess ("NHRI"), which was
part of the psilocybin program acquired from PharmaTher Inc., a
subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF).
The
study
characterized the
potential neuroreparative
effect
of
psilocybin
compared
to being treated with a
vehicle (saline)
using
a TBI
mouse model. Adult mice
were randomly assigned to 4 groups: (1) control, (2) TBI+vehicle,
(3) TBI+low dose psilocybin, and (4) high dose psilocybin.
Cognitive function was examined by the Morris water maze test after
the injury. It was found
that psilocybin, given
after injury, improved cognitive
function in TBI mice.
Also,
there were no adverse effects observed with
psilocybin.
With
the its
recent
acquisition of the provisional
patent application
from
PharmaTher Inc.,
titled, "Psilocybin
in the Treatment of Neurological Brain Injury",
and the
positive research results with psilocybin in a TBI model, Revive
has filed an international
Patent Cooperation Treaty ("PCT")
application
(PCT/CA2021/050360)
allowing
it
to seek protection of this invention
in
153 countries, including the U.S., Europe, Canada,
Japan and China.
Michael
Frank, CEO of Revive commented: "We are pleased with
the results from our psilocybin research study in TBI as it
strengthens our intellectual property portfolio for novel uses of
psilocybin and it
complements
our robust psilocybin-based
portfolio that includes the
development of an oral thin film product in collaboration with the
University of Wisconsin-Madison, a novel biosynthetic version of
psilocybin based on a natural biosynthesis enzymatic platform
developed by Dr. Gavin Williams, Professor and Researcher at North
Carolina State University, and
a
clinical study with the University of Wisconsin evaluating
psilocybin in the treatment of methamphetamine use
disorder. We are focused on
advancing psilocybin to treat mild
TBI,
also commonly known as
concussions."
According to the CDC,
there
were about
2.87 million TBI-related emergency department visits
and
hospitalizations
annually in the U.S. A TBI is mostly
caused by a bump, blow, or jolt to the head that disrupts the
normal function of the brain. Most TBIs that occur each year are
mild, also referred
to as
concussions. According to Stanford
Children's Health, over 3.5 million sports-related injuries are
reported annually among children in the U.S. and around 21% of all
are traumatic brain injuries. There is
aS significant
need
for new treatment
solutions for TBI. are
needed.
About
Revive Therapeutics Ltd.
Revive is
a life sciences company focused on the research and development of
therapeutics for infectious diseases and rare disorders, and it is
prioritizing drug development efforts to take advantage of
several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat
autoimmune hepatitis (liver disease) and to treat ischemia and
reperfusion injury from organ transplantation. For more
information, visit
www.ReviveThera.com.
For more
information, please contact:
Michael
Frank
Chief
Executive Officer
Revive
Therapeutics Ltd.
Tel: 1
888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider has reviewed or accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the
the
Company's cannabinoids, psychedelics and infectious diseases
programs.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or
otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking
information contained herein. Reference is made to the risk factors
disclosed under the heading "Risk Factors" in the Company's annual
MD&A for the fiscal year ended June 30, 2020, which has been
filed on SEDAR and is available under the Company's profile
at www.sedar.com.